Data investigation

Utah Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

Utah Medicaid's legislative pilot covering Saxenda, Wegovy, and Zepbound for chronic weight management EXPIRED June 30, 2026 without renewal — the PA form was reissued as 'GLP-1 Medications for Weight-related Comorbidities' (6/1/26): MACE, OSA, and MASH pathways only.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
18 min read·9 citations

TL;DR

Utah Medicaid (administered by the Utah Department of Health and Human Services) was structurally unique: chronic-weight-management coverage existed only through June 30, 2026 under a legislative pilot program — and the pilot expired on that date without renewal. The pilot-era Utah Medicaid Pharmacy PA form — titled “GLP-1 Medications for Weight Loss and Other Indications (Saxenda, Wegovy, Zepbound)” and last updated January 1, 2026 — required three separate provider attestations (Part 2 adult, Part 3 pediatric, Part 10 reauthorization) verbatim:

“Does the provider attest that they are aware that coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026?”

The Authorization Duration section stated verbatim:

“Obesity (Saxenda/Zepbound/Wegovy): Up to and no later than 6/30/2026*, initial and reauthorizations

* Coverage for weight-loss is part of a pilot program and may not continue past 6/30/2026.”

What happened (verified August 25, 2026): of the three possible outcomes — extension, conversion to a permanent benefit, or sunset without renewal — the third occurred. The 2026 legislative session did not renew the Medicaid pilot (it instead created a separate GLP-1 pilot for PEHP public employees), and Saxenda / Wegovy / Zepbound coverage for chronic weight management in Utah Medicaid ended June 30, 2026. Utah Medicaid reissued the PA form as “GLP-1 Medications for Weight-related Comorbidities” (Last Updated June 1, 2026): initial approval is limited to MACE (Wegovy), OSA (Zepbound), and MASH (Wegovy), and the obesity pathway was reauthorization-only “Up to and no later than 6/30/2026.”

Three indication-permanent carve-outs continue indefinitely post-sunset (NOT subject to the June 30, 2026 deadline):

IndicationDrugInitial PAReauthorization
Cardiovascular MACE (secondary prevention)WegovyUp to 6 monthsUp to 12 months
Moderate-to-severe OSAZepboundUp to 12 monthsUp to 12 months
Noncirrhotic MASH (F2–F3 fibrosis)WegovyUp to 6 monthsUp to 12 months

Architectural distinctive features:

  • Unified 11-part PA form. Utah used a single document covering Saxenda + Wegovy + Zepbound across six indications (adult weight loss, pediatric weight loss, Wegovy MACE, Zepbound OSA, Wegovy MASH, plus reauthorization paths) in one PDF. Arkansas uses three separate DUR-Board documents; West Virginia combines Wegovy CV+MASH in one document but separates Zepbound OSA. Utah was the only state with all indications in one form; the reissued June 1, 2026 form keeps the unified structure for the three surviving indications.
  • Strictest OSA criteria in the series. Zepbound OSA requires in-lab attended PSG (not home sleep test) for AHI documentation AND ≥ 70% PAP adherence over the last 6 months. WV only requires CPAP counseling; AR requires CPAP failure but does not specify a 70% adherence threshold. Utah's 70% PAP-adherence bar is unique.
  • Dual-modality MASH confirmation. Wegovy MASH requires both a FIB-4 score consistent with F2 or F3 fibrosis (adjusted for age) AND ONE of: liver biopsy, vibration-controlled transient elastography (VCTE), enhanced liver fibrosis (ELF) score, or magnetic resonance elastography (MRE). Most other states accept biopsy OR imaging singly.
  • Guideline-recommended MACE secondary prevention required. Wegovy MACE coverage requires the patient to be concurrently taking guideline-recommended cardiovascular secondary-prevention measures (typically statin + antiplatelet + BP control). Most other states do not explicitly require concurrent guideline-recommended prevention as a coverage gate.
  • Pediatric coverage was limited to Saxenda + Wegovy. Pediatric (ages 12–17) weight management was available through the pilot for Wegovy or Saxenda only — Zepbound was NOT a pediatric-eligible drug under Utah Medicaid even during the pilot period. The reissued June 1, 2026 form no longer includes a pediatric pathway; Utah's current pediatric coverage status is unverified — confirm with Utah Medicaid directly.

Medicaid expansion status: Utah voters approved Proposition 3 (full Medicaid expansion to 138% FPL) by ballot initiative in November 2018. After 2019 legislative modifications (Senate Bills 96 and 4001), Utah implemented full Medicaid expansion effective January 1, 2020. Approximately 350,000–400,000 Utahns are enrolled in Medicaid as of 2026 including the expansion population.

Pharmacy PA submission: fax the completed form with chart notes and lab results to Pharmacy Prior Authorization Team at 855-828-4992. Prescriber NPI required.

1. The June 30, 2026 pilot program sunset

The defining feature of Utah Medicaid's GLP-1 coverage architecture was the legislative pilot program with an explicit sunset date of June 30, 2026. The pilot operated at the Utah Medicaid pharmacy benefit level and was operationalized through the Utah Medicaid Pharmacy Prior Authorization Request Form for “GLP-1 Medications for Weight Loss and Other Indications.” The pilot expired June 30, 2026 without renewal, and the form was reissued (Last Updated June 1, 2026) as “GLP-1 Medications for Weight-related Comorbidities.”

1.1 Verbatim sunset language from the PA form

The pilot-sunset attestation appeared three times in the pilot-era PA form — signaling that Utah Medicaid wanted prescribers to be unambiguously aware of the sunset risk before initiating therapy and at each reauthorization:

  • PA form Part 2 (adult weight loss, item 10): “Does the provider attest that they are aware that coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026?”
  • PA form Part 3 (pediatric weight loss, item 14): Same attestation language for pediatric requests.
  • PA form Part 10 (weight-loss reauthorization, item 12): Same attestation language at reauthorization.

The Authorization Duration section of the pilot-era PA form stated verbatim:

“Obesity (Saxenda/Zepbound/Wegovy): Up to and no later than 6/30/2026*, initial and reauthorizations

MACE (Wegovy): Up to six (6) months initial authorization, up to twelve (12) months reauthorization

Moderate/Severe OSA (Zepbound): Up to twelve (12) months, initial and reauthorizations

MASH (Wegovy): Up to six (6) months initial authorization, up to twelve (12) months reauthorization

* Coverage for weight-loss is part of a pilot program and may not continue past 6/30/2026.”

1.2 What we know vs. what we don't

Verified primary-source facts:

  • Coverage of Saxenda, Wegovy, and Zepbound for chronic weight management in Utah Medicaid was part of a legislatively-authorized pilot program.
  • The sunset date was June 30, 2026 — and it executed: the pilot expired on that date without renewal.
  • No initial PA or reauthorization for chronic weight management could extend past June 30, 2026 under the pilot authorization.
  • The three indication-permanent carve-outs (Wegovy MACE, Zepbound OSA, Wegovy MASH) are NOT subject to the sunset and operate on standard PA approval periods (6 months initial / 12 months reauth for Wegovy MACE and Wegovy MASH; 12 months initial AND reauth for Zepbound OSA).

What the pilot-era PA form did NOT specify:

  • The specific Utah statute or session law authorizing the pilot.
  • The pilot's renewal mechanism — whether the Utah Legislature had to affirmatively act to extend, or whether the Utah Medicaid program could administratively continue coverage under a different authority post-sunset. (In the event, no renewal occurred and coverage ended.)
  • Whether the pilot was funded by a specific appropriation that also sunset June 30, 2026, or whether funding continued independently.
  • The fiscal year 2026 spend or beneficiary count under the pilot.

The renewal question resolved without an extension: the pilot expired June 30, 2026, and the 2026 legislative session created a GLP-1 pilot for PEHP public employees instead of renewing the Medicaid one. Utah Medicaid's reissued PA form (Last Updated June 1, 2026), retitled “GLP-1 Medications for Weight-related Comorbidities,” carries initial-approval pathways for MACE (Wegovy), OSA (Zepbound), and MASH (Wegovy) only; obesity approvals were reauthorization-only “Up to and no later than 6/30/2026.” (Verified August 25, 2026.)

2. Universal criteria across all 6 indication pathways (PA Form Part 1)

All six pilot-era PA-form pathways (adult weight loss, pediatric weight loss, Wegovy MACE, Zepbound OSA, Wegovy MASH) shared the same Part 1 universal criteria. Verbatim from the pilot-era form:

“PART 1 - Criteria for Approval: (All of the following criteria must be met)

1. What is the patient's current Weight, Height, BMI, Age?

2. Is the patient on a medically appropriate exercise program and an appropriate calorie-restricted diet, that they will continue while using the medication presented in the chart note?

3. Does the provider attest that the patient has no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2?

4. Does the provider attest that the patient is NOT pregnant?

5. Does the provider attest that the patient is NOT taking another glucagon-like peptide-1 (GLP-1) receptor agonist, a glucose-dependent insulinotropic peptide (GIP), or a dipeptidyl peptidase-4 (DPP4) inhibitor?

6. Does the prescriber attest that doses of the medication will be titrated to the required minimum dose required for reauthorization, within 6 months of initiation, as appropriate?”

These six universal criteria mirror the FDA-label contraindications for Wegovy, Saxenda, and Zepbound:

  • MTC/MEN2 contraindication — standard FDA label warning for all GLP-1 receptor agonists.
  • Pregnancy exclusion — standard FDA Category warning.
  • Concurrent GLP-1/GIP/DPP-4 exclusion — prevents formulary cross-utilization between Antiobesity Select Agents and Hypoglycemics-Incretin Mimetics classes, and reinforces one-at-a-time rule across drug classes.
  • Lifestyle attestation — reduced-calorie diet and increased physical activity must be in place AND continuing during therapy.
  • Dose titration commitment — doses must be titrated to the required minimum maintenance dose within 6 months of initiation. This prevents low-dose maintenance prescribing and ensures patients reach the therapeutic dose range for the FDA-approved indication.

The PA form's Part 1 also included the FDA suicidality monitoring note verbatim:

“The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.”

3. Adult weight management criteria (PA Form Part 2)

This pathway ended with the pilot on June 30, 2026; the criteria below are the pilot-era record.

“PART 2 - Adult Weight Loss - Additional Criteria for Approval: (All of the following criteria must be met)

8. Is the patient 18 years of age or older?

9. Does the patient have a diagnosis of one of the following?

Obesity (BMI ≥ 30 kg/m²)

Overweight (BMI 27-29.9 kg/m²) and at least one weight-related comorbidity (e.g. hypertension, dyslipidemia, etc.) Comorbidities: ______________________________________

10. Does the provider attest that they are aware that coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026?”

Operational note: Utah did not require additional comorbidity-specific lab values (HbA1c for diabetes, lipid panel for hyperlipidemia, sleep study for OSA) at the BMI 27–29.9 tier — the provider attested to the comorbidity diagnosis on the form. This was more permissive than states like Mississippi , which requires claims-history or lab-value confirmation of comorbidities. Utah's permissive approach reflected the pilot-program nature of the coverage.

4. Pediatric weight management criteria (PA Form Part 3)

This pathway ended with the pilot on June 30, 2026. The reissued June 1, 2026 form carries no pediatric weight-management pathway; Utah's current pediatric coverage status is unverified — confirm with Utah Medicaid directly.

“PART 3 - Pediatric Weight Loss - Additional Criteria for Approval: (All of the following criteria must be met)

11. Is the patient 12 to 17 years old?

12. Is the request for Wegovy or Saxenda?

13. Is the patient's BMI ≥ 95th percentile for their age and sex?

14. Does the provider attest that they are aware that coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026?”

Critical operational facts for the Utah pediatric weight management pathway:

  • Ages 12–17 only. No coverage for ages under 12 or 18+ existed under the pilot.
  • Wegovy or Saxenda only. Zepbound was excluded from pediatric coverage in Utah even during the pilot. This aligned with FDA pediatric labeling (Wegovy approved ages 12+; Saxenda approved ages 12+ with body weight requirements; Zepbound not pediatric-approved as of May 2026).
  • BMI ≥ 95th percentile for age and sex — the standard CDC growth-chart obesity definition for pediatric patients. The form did not reproduce the CDC table inline (unlike Mississippi, which embeds the CDC table in the PA form) but references the standard percentile definition.

Utah and Mississippi were the two states in the 37-state series with explicit pediatric chronic-weight-management Medicaid GLP-1 coverage. The two states differed in important ways:

  • Utah: pilot-program with June 30, 2026 sunset (expired; not renewed); Wegovy and Saxenda only; BMI ≥ 95th percentile criterion; same PA form as adult.
  • Mississippi: permanent coverage via SPA 23-0013 since July 1, 2023; Wegovy and Saxenda only; CDC growth-chart table embedded in PA form; Saxenda requires body weight > 60 kg additionally.

5. Wegovy MACE criteria (PA Form Part 4 — NOT subject to sunset)

“PART 4 - Wegovy for MACE - Additional Criteria for Approval: (All of the following criteria must be met)

15. Is the patient 18 years of age or older?

16. Does the patient have a Body Mass Index (BMI) of ≥ 27 kg/m²?

17. Does the patient have a past medical history of at least one of the following:

Myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)

Stroke (hemorrhagic or ischemic)

Symptomatic peripheral arterial disease, as evidenced by intermittent claudication with ankle-brachial index less than 0.85, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

18. Is the patient currently taking guideline-recommended measures for the secondary prevention of a major adverse cardiovascular event (MACE)?”

Initial PA: up to 6 months. Reauthorization: up to 12 months, requires titration to Wegovy 2.4 mg dose AND ≥ 5% baseline body weight loss after 20 weeks (maintained) AND continued guideline-recommended MACE secondary prevention.

Two operationally distinctive Utah features:

  • Past-MI flexibility: Utah accepts past myocardial infarction OR percutaneous coronary intervention (PCI) OR coronary artery bypass grafting (CABG) as the cardiac qualifying event. West Virginia and Arkansas require past MI more specifically. Utah's acceptance of PCI/CABG widens the qualifying population.
  • Guideline-recommended secondary prevention required (item 18) — the patient must be concurrently taking guideline-recommended MACE secondary prevention measures (typically statin + antiplatelet + BP control for prior MI/stroke; ABI-appropriate management for PAD). Most other states in the 37-state series do not explicitly require concurrent guideline-recommended prevention as a coverage gate.

Note that Utah does NOT have the West Virginia HbA1c ≤ 6.5% diabetic-exclusion gate — T2D patients with established CVD can qualify for Wegovy MACE in Utah (subject to the Part 1 no-other-GLP-1/GIP/DPP-4 exclusion, which they would need to satisfy by going off any concurrent T2D-indicated GLP-1).

6. Zepbound OSA criteria (PA Form Part 5 — strictest in series)

“PART 5 - Zepbound for OSA - Additional Criteria for Approval: (All of the following criteria must be met)

19. Is the patient 18 years of age or older?

20. Is the medication being prescribed by or in consultation with a neurologist, pulmonologist, otolaryngologist, or other sleep medicine specialist?

21. Does the patient have a body mass index (BMI) of greater than or equal to 30 kg/m²?

22. Does the patient have a diagnosis of moderate-to severe obstructive sleep apnea (OSA) confirmed by an apnea-hypopnea index (AHI) of 15 or higher as determined by an in-lab attended sleep study or polysomnography (PSG)?

Baseline AHI score: __________________________

23. Has the patient been adherent to positive airway pressure (PAP) for at least 70% in the last 6 months and will continue on PAP in combination with Zepbound, unless intolerant or other rationale is given?”

Initial PA: up to 12 months. Reauthorization: up to 12 months, requires AHI decrease ≥ 20% from baseline OR shift to Mild Non-Symptomatic OSA (AHI < 5 OR AHI 5–14 with Epworth Sleepiness Scale ≤ 10); continued ≥ 70% PAP adherence.

Utah's OSA criteria are the strictest in the 37-state series:

  • In-lab attended PSG required — not home sleep tests, not portable monitoring. This excludes patients who were diagnosed with OSA via home sleep test only. Utah is the only state in the series with this in-lab-PSG-only requirement.
  • 70% PAP adherence in last 6 months required at initial PA — the patient must already be using PAP compliantly before Zepbound OSA approval. WV only requires CPAP counseling (not adherence); AR requires CPAP failure but does not specify adherence percentage. Utah's 70%-adherence bar reflects sleep-medicine clinical-practice standards for adequate PAP therapy.
  • Specialist consultation required — neurologist, pulmonologist, otolaryngologist, or sleep medicine specialist must prescribe or consult. Primary-care physicians cannot independently prescribe Zepbound OSA in Utah.
  • Reauthorization requires either ≥ 20% AHI reduction OR shift to Mild Non-Symptomatic OSA — with both clinical metric and symptom assessment (Epworth Sleepiness Scale).

Utah does NOT have the West Virginia T2D step-therapy bridge (which requires T2D patients to first fail a preferred T2D GLP-1 for 3 months before Zepbound OSA). Utah's no-concurrent-GLP-1 rule at Part 1 item 5 effectively requires T2D patients to be off any T2D-indicated GLP-1 to qualify for Zepbound OSA, but does not require demonstrated treatment failure of a T2D GLP-1 first.

7. Wegovy MASH criteria (PA Form Part 6 — dual-modality required)

“PART 6 - Wegovy for MASH - Additional Criteria for Approval: (All of the following criteria must be met)

24. Is the patient 18 years of age or older?

25. Does the patient have a diagnosis of metabolic dysfunction associated steatohepatitis (MASH), or formerly known as noncirrhotic nonalcoholic steatohepatitis (NASH)?

26. Is the medication being prescribed by or in consultation with a gastroenterologist, hepatologist, or other liver disease specialist?

27. Does the patient have moderate to advanced liver fibrosis (stage F2 to F3) as confirmed by:

a. A FIB-4 score consistent with stage F2, or F3 fibrosis adjusted for age AND

b. ONE of the following:

A liver biopsy

Vibration-controlled transient elastography (VCTE)

Enhanced liver fibrosis (ELF) score

Magnetic resonance elastography (MRE)

28. Does the provider attest the patient does NOT have ANY of the following?

a. Decompensated cirrhosis

b. Moderate to severe hepatic impairment (Child-Pugh Class B or C)

c. Any other liver disease (e.g., hepatocellular carcinoma, hepatitis)”

Initial PA: up to 6 months. Reauthorization: up to 12 months, requires Wegovy maintenance on 2.4 mg (or 1.7 mg if higher dose intolerable after 17 weeks) AND updated chart notes demonstrating positive clinical response (improvement in symptoms and/or improvement in routine monitoring such as FIB-4 score or serum aminotransferases).

Utah's MASH dual-modality requirement is structurally distinctive. The patient must satisfy BOTH:

  • FIB-4 score consistent with F2 or F3 fibrosis adjusted for age — a calculated index based on age, AST, ALT, and platelet count.
  • ONE of: liver biopsy, VCTE (FibroScan), ELF score, or MRE — an imaging or biopsy modality.

West Virginia accepts biopsy OR FibroScan/MRE singly without a parallel FIB-4 requirement. Arkansas similarly. Utah is the only state in the series requiring both a blood-based fibrosis index AND an imaging/biopsy modality — a more rigorous fibrosis-confirmation standard.

Liver-disease exclusions (item 28) are also more specific than other states: decompensated cirrhosis, Child-Pugh Class B or C (moderate-to-severe hepatic impairment), and any other liver disease including hepatocellular carcinoma or hepatitis. Patients with viral hepatitis (HBV or HCV) would not qualify for Wegovy MASH in Utah even if they meet F2–F3 fibrosis criteria, because viral hepatitis is “another liver disease” under item 28(c).

8. Reauthorization criteria (PA Form Parts 7–11)

Reauthorization across all indications shares a common Part 7 framework (current weight/height/BMI/age, continued adherence to exercise and calorie-restricted diet) plus indication-specific additional criteria in Parts 8–11.

8.1 Wegovy MACE reauthorization (Part 8)

  • Patient titrated up to or taking the Wegovy 2.4 mg dose.
  • Initial weight loss of ≥ 5% from baseline body weight after 20 weeks AND maintained.
  • Continued guideline-recommended MACE secondary prevention.

8.2 Zepbound OSA reauthorization (Part 9)

  • AHI decrease from baseline ≥ 20% OR shift to Mild Non-Symptomatic OSA (defined as AHI < 5 OR AHI 5–14 with Epworth Sleepiness Scale ≤ 10).
  • ≥ 70% PAP adherence in last 6 months AND continued PAP use with Zepbound (unless intolerant or other rationale).

8.3 Adult/pediatric weight loss reauthorization (Part 10)

  • ≥ 5% weight loss from baseline. (Weight-loss reauthorizations could not extend past June 30, 2026; this pathway is now closed.)
  • Patient titrated up and currently taking at least the minimum required maintenance dose after 6 months of treatment:
    • Saxenda (adult 18+): 3 mg daily
    • Saxenda (pediatric 12–17): 2.4 mg daily
    • Wegovy: 1.7 mg per week
    • Zepbound: 5 mg per week
  • Provider pilot-sunset attestation (third occurrence in the form).

8.4 Wegovy MASH reauthorization (Part 11)

  • Patient maintained on Wegovy 2.4 mg (or 1.7 mg if higher dose cannot be tolerated after 17 weeks).
  • Updated chart notes demonstrating positive clinical response (improvement in symptoms; improvement in routine monitoring such as FIB-4 score or serum aminotransferases).

9. Utah vs. the 37-state taxonomy

9.1 Utah's structural uniqueness

  • Only state with a legislative pilot-program sunset date attached to chronic-weight-management coverage. The June 30, 2026 sunset created an unusual time-sensitive coverage architecture — and it executed: the pilot expired on that date without renewal.
  • Only state with a unified PA form across all 6 GLP-1 indications (pilot-era; the reissued June 1, 2026 form covers the three surviving indications). All other states use separate documents per indication (or combine two related indications, as WV does with Wegovy CV+MASH).
  • Strictest OSA criteria in the series: in-lab attended PSG only + 70% PAP adherence required.
  • Only state with dual-modality MASH confirmation (FIB-4 PLUS one imaging/biopsy).
  • Concurrent guideline-recommended MACE secondary prevention required — explicit gate not used by most other states.

9.2 Closest peers

  • Mississippi — the other state in the series with operationalized pediatric (ages 12+) chronic-weight-management coverage. MS coverage is permanent (via SPA 23-0013 effective July 1, 2023); UT coverage was a pilot that expired June 30, 2026. Both covered Wegovy + Saxenda for ages 12+ (UT excluded Zepbound from pediatric; MS does not cover Zepbound at all).
  • West Virginia — same three FDA-label carve-outs (Wegovy CV + Wegovy MASH + Zepbound OSA). UT added chronic-weight-management coverage during the pilot (expired June 30, 2026); WV never did. UT requires 70% PAP adherence for OSA; WV only requires CPAP counseling. UT requires dual-modality MASH confirmation; WV accepts biopsy or imaging singly.
  • Oklahoma — four FDA-label carve-outs (adds Imcivree monogenic-obesity). OK uses OU College of Pharmacy / PMC for PA; UT uses the standard Utah Medicaid Pharmacy PA Team. Both states are expansion states (OK via SQ 802 July 2021; UT effective January 1, 2020).
  • Arkansas — three FDA-label carve-outs via three separate DUR-Board PA documents. AR has ACT 628 legislative-ratification layer affirming exclusion of chronic weight management; UT had the opposite legislative posture — a pilot program affirming temporary coverage, which expired June 30, 2026.

What Utah Medicaid actually spends on GLP-1s

Utah reports every Medicaid prescription and dollar it pays for each drug to CMS quarterly. In 2025, Utah Medicaid paid $29M gross for GLP-1 medications across 27,850 prescriptions, with drugs labeled for weight loss (Wegovy, Zepbound, Saxenda) making up 1% of that spending. Figures are before confidential rebates — net cost is substantially lower.

QuarterWegovy rxOzempic rxAll GLP-1 gross
Q1 2025—2,442$7M
Q2 2025112,463$7M
Q3 2025—2,276$7M
Q4 2025382,436$8M
Q1 2026(preliminary)1323,901$8M

Source: CMS Medicaid State Drug Utilization Data, fee-for-service and managed care combined; quarters with small cell counts are partially suppressed by CMS, so affected figures are floors. The latest quarter fills in as Utah files late reports. See the national Medicaid GLP-1 spending tracker for every state, or download the full dataset (CSV).

10. Appeals pathway and pilot-sunset planning

Utah Medicaid appeals run through the Utah Department of Health and Human Services administrative-hearing process and 42 C.F.R. § 431 Subpart E (federal Fair Hearings framework).

Practical denial-recovery path for a Utah Medicaid GLP-1 PA denial:

  1. Contact Pharmacy PA Team at 855-828-4992 to verify denial rationale (often documentation deficiency, not categorical denial).
  2. Re-submit PA with additional documentation: ensure all six Part 1 universal criteria attested; ensure indication-specific Part 2–6 documentation complete and specific. For OSA in particular, ensure the in-lab attended PSG report (not home test) is attached and the 70% PAP adherence report from the CPAP device is downloaded and included. For MASH, ensure both FIB-4 calculation AND one imaging/biopsy modality are documented.
  3. If denial stands, file request for fair hearing through Utah DHHS Medicaid.
  4. Hearing before an administrative law judge with the right to representation and to introduce evidence.
  5. Final agency decision.
  6. Judicial review in Utah district court.

10.1 Pilot-sunset planning

The pilot expired June 30, 2026 without renewal. For patients who were on Saxenda, Wegovy, or Zepbound for chronic weight management under the Utah Medicaid pilot, the practical picture now:

  • The renewal did not happen — the 2026 legislative session created a separate GLP-1 pilot for PEHP public employees instead of renewing the Medicaid pilot.
  • Discuss with prescriber whether a transition to a different indication-permanent pathway is clinically appropriate (e.g., if the patient has established CVD, transition to Wegovy MACE; if the patient has confirmed F2–F3 MASH, transition to Wegovy MASH; if the patient has confirmed moderate-to-severe OSA, transition to Zepbound OSA).
  • Cash-pay is the fallback now that weight-loss coverage ended July 1, 2026 — NovoCare offers Wegovy at $349/month ongoing self-pay (or $199/month for new patients first 2 months); LillyDirect offers Zepbound vials at $299–$699/month depending on dose; compounded alternatives also available. Compare current cash prices in our GLP-1 pricing index and the cheapest semaglutide options.
  • With the pilot expired, an appeal of a post-sunset chronic-weight-management denial is structurally very unlikely to succeed — the denial is anchored to the absent legislative authority for coverage and is not overturnable at the agency level.

Further reading

Frequently Asked Questions

Not anymore for weight loss. Utah Medicaid covered Saxenda, Wegovy, and Zepbound for chronic weight management under a legislative pilot program that EXPIRED June 30, 2026 without renewal. The pilot-era PA form — titled 'GLP-1 Medications for Weight Loss and Other Indications (Saxenda, Wegovy, Zepbound)', last updated January 1, 2026 — required prescribers to attest verbatim: 'Does the provider attest that they are aware that coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026?' That warning came true: the form has been reissued as 'GLP-1 Medications for Weight-related Comorbidities' (Last Updated June 1, 2026), with initial-approval pathways for MACE (Wegovy), OSA (Zepbound), and MASH (Wegovy) only; the obesity pathway was reauthorization-only 'Up to and no later than 6/30/2026.' The three carve-out indications continue with prior authorization.
The Utah Medicaid GLP-1 pilot program was a legislatively-authorized coverage demonstration that included Saxenda, Wegovy, and Zepbound for chronic weight management in adults (18+) and pediatric patients (ages 12-17). The pilot was operationalized through the Utah Medicaid Pharmacy PA form 'GLP-1 Medications for Weight Loss and Other Indications' with explicit pilot-sunset attestations; the form referenced it as a 'legislative pilot program' with a sunset date of June 30, 2026. The pilot expired on that date and was not renewed — the 2026 legislative session instead created a separate GLP-1 pilot for PEHP public employees, not Medicaid. Utah Medicaid weight-loss GLP-1 coverage ended June 30, 2026; the MACE, OSA, and MASH carve-outs continue on the reissued form.
This pathway ended with the pilot on June 30, 2026 — the reissued June 1, 2026 form carries no weight-loss initial-approval pathway. For the historical record, the pilot-era PA form Parts 1+2 adult (18+) chronic weight management criteria required: (1) patient age ≥ 18; (2) diagnosis of obesity (BMI ≥ 30 kg/m²) OR overweight (BMI 27-29.9 kg/m²) plus at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, etc.); (3) patient on a medically appropriate exercise program and appropriate calorie-restricted diet, continuing while on medication; (4) provider attestation: no personal or family history of medullary thyroid carcinoma or MEN type 2; (5) patient not pregnant; (6) patient not taking another GLP-1 receptor agonist, a glucose-dependent insulinotropic peptide (GIP), or a dipeptidyl peptidase-4 (DPP-4) inhibitor; (7) prescriber attests doses will be titrated to the minimum required maintenance dose within 6 months; (8) prescriber attests awareness that coverage may not continue past June 30, 2026 (pilot sunset). Initial authorization period: 'up to and no later than 6/30/2026.'
During the pilot (which expired June 30, 2026), the Utah Medicaid PA form Parts 1+3 pediatric (ages 12-17) chronic weight management criteria required: (1) patient age 12 to 17 (inclusive); (2) request must be for Wegovy or Saxenda specifically (Zepbound is NOT covered for pediatric patients per the Utah PA form); (3) BMI ≥ 95th percentile for age and sex; (4) patient on a medically appropriate exercise program and calorie-restricted diet, continuing while on medication; (5) no MTC/MEN2 history; (6) patient not pregnant; (7) no other GLP-1/GIP/DPP-4 concurrent use; (8) dose titration to minimum maintenance within 6 months; (9) provider attestation of pilot-sunset awareness (June 30, 2026). Utah Medicaid was one of only a handful of states with operationalized pediatric chronic-weight-management coverage — alongside Mississippi which similarly extends to ages 12+. The reissued June 1, 2026 form no longer includes a pediatric weight-management pathway; Utah's current pediatric coverage status is unverified — confirm directly with Utah Medicaid before assuming coverage either way.
Per the Utah Medicaid PA form Parts 1+4, Wegovy for MACE (major adverse cardiovascular event secondary prevention) criteria require: (1) patient age ≥ 18; (2) BMI ≥ 27 kg/m²; (3) past medical history of at least ONE of: myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG); OR hemorrhagic or ischemic stroke; OR symptomatic peripheral arterial disease evidenced by intermittent claudication with ankle-brachial index less than 0.85, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease; (4) currently taking guideline-recommended measures for the secondary prevention of MACE (a structurally distinctive Utah requirement — not all states require concurrent guideline-recommended secondary-prevention therapies); (5) no MTC/MEN2; (6) not pregnant; (7) no other GLP-1/GIP/DPP-4. Initial PA: up to 6 months. Reauthorization: up to 12 months, requires titration to Wegovy 2.4 mg dose AND ≥ 5% baseline body weight loss after 20 weeks (maintained), AND continued guideline-recommended MACE secondary prevention. Wegovy MACE coverage was NOT subject to the June 30, 2026 pilot sunset and continues as an initial-approval pathway on the reissued June 1, 2026 form.
Per the Utah Medicaid PA form Parts 1+5, Zepbound for moderate-to-severe OSA criteria require: (1) patient age ≥ 18; (2) prescribed by or in consultation with a neurologist, pulmonologist, otolaryngologist, or other sleep medicine specialist; (3) BMI ≥ 30 kg/m²; (4) moderate-to-severe OSA confirmed by apnea-hypopnea index (AHI) ≥ 15 as determined by an in-lab attended sleep study or polysomnography (PSG) — Utah uniquely requires in-lab attended PSG, not home sleep tests; (5) patient adherent to positive airway pressure (PAP) for at least 70% in the last 6 months AND will continue PAP in combination with Zepbound unless intolerant or other rationale is given. Initial PA: up to 12 months. Reauthorization: up to 12 months, requires AHI decrease ≥ 20% from baseline OR shift to Mild Non-Symptomatic OSA (AHI < 5 or AHI 5-14 with Epworth Sleepiness Scale ≤ 10); continued ≥ 70% PAP adherence. The 70% PAP adherence requirement is structurally distinctive — only a handful of states mandate documented PAP adherence at this threshold for Zepbound OSA approval. Zepbound OSA coverage was NOT subject to the June 30, 2026 pilot sunset and continues as an initial-approval pathway on the reissued June 1, 2026 form.
Per the Utah Medicaid PA form Parts 1+6, Wegovy for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) criteria require: (1) patient age ≥ 18; (2) MASH diagnosis confirmed; (3) prescribed by or in consultation with a gastroenterologist, hepatologist, or other liver disease specialist; (4) moderate-to-advanced liver fibrosis (stage F2 to F3) confirmed by BOTH a FIB-4 score consistent with stage F2 or F3 fibrosis adjusted for age AND ONE of: liver biopsy, vibration-controlled transient elastography (VCTE), enhanced liver fibrosis (ELF) score, or magnetic resonance elastography (MRE) — Utah uniquely requires the DUAL-MODALITY confirmation (FIB-4 PLUS one imaging or biopsy modality); (5) provider attests patient does NOT have decompensated cirrhosis, Child-Pugh Class B or C, or other liver disease (hepatocellular carcinoma, hepatitis); (6) no MTC/MEN2; (7) not pregnant; (8) no other GLP-1/GIP/DPP-4. Initial PA: up to 6 months. Reauthorization: up to 12 months, requires Wegovy maintenance on 2.4 mg (or 1.7 mg if higher dose intolerable after 17 weeks) AND updated chart notes demonstrating positive clinical response (improvement in symptoms and/or routine monitoring such as FIB-4 score or serum aminotransferases). Wegovy MASH coverage was NOT subject to the June 30, 2026 pilot sunset and continues as an initial-approval pathway on the reissued June 1, 2026 form.
The question is now answered: the pilot expired June 30, 2026 without renewal, ending Saxenda/Wegovy/Zepbound coverage for chronic weight management in Utah Medicaid — the third of the three possible outcomes (extension, permanence, or sunset without renewal). The 2026 legislative session did not renew the Medicaid pilot; it instead created a separate GLP-1 pilot for PEHP public employees. Utah Medicaid reissued its PA form as 'GLP-1 Medications for Weight-related Comorbidities' (Last Updated June 1, 2026): initial approval is limited to MACE (Wegovy), OSA (Zepbound), and MASH (Wegovy); the obesity pathway was reauthorization-only 'Up to and no later than 6/30/2026,' with the attestation that 'coverage for weight management is part of a legislative pilot program and may not continue past 6/30/2026.' The three indication-permanent carve-outs (Wegovy MACE, Zepbound OSA, Wegovy MASH) were NOT subject to the sunset and continue.
Per Utah Medicaid PA form Part 1 (on the pilot-era form this applied to all six indication pathways — adult weight loss, pediatric weight loss, Wegovy MACE, Zepbound OSA, Wegovy MASH; the surviving MACE/OSA/MASH pathways continue on the reissued form), universal exclusion criteria require provider attestation that the patient does NOT have: (1) personal or family history of medullary thyroid carcinoma (MTC); (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); (3) current pregnancy; (4) concurrent use of another GLP-1 receptor agonist, glucose-dependent insulinotropic peptide (GIP) (Zepbound is itself a GIP/GLP-1 dual agonist — these criteria preclude OTHER GIP/GLP-1 concurrent therapy), or dipeptidyl peptidase-4 (DPP-4) inhibitor. Universal criteria also require: (5) the patient is on a medically appropriate exercise program and calorie-restricted diet; (6) prescriber attests doses will be titrated to the required minimum maintenance dose within 6 months. The FDA-suicidality monitoring note is included in the form: 'The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue.'
Per the Utah Medicaid PA form instructions: 'Fax form and relevant documentation including: laboratory results, chart notes and/or updated provider letter to Pharmacy PA at 855-828-4992, to prevent processing delays.' The form requires verbatim: '*Pharmacy prior authorizations must be initiated by a Medicaid prescriber.' Required documentation by indication: adult/pediatric weight management (pilot-era pathway — closed since June 30, 2026) — current weight, height, BMI, exercise/diet attestation, MTC/MEN2/pregnancy/GLP-1-naive attestations, pilot-sunset attestation; Wegovy MACE — BMI ≥ 27 documentation, MI/PCI/CABG/stroke/PAD evidence (with ABI documentation if PAD), guideline-recommended secondary prevention; Zepbound OSA — in-lab attended PSG with AHI documentation, BMI ≥ 30 within 3 months, 70% PAP adherence in last 6 months, sleep specialist consultation; Wegovy MASH — FIB-4 score + one of liver biopsy/VCTE/ELF score/MRE result, GI/hepatology consult, no decompensated cirrhosis or Child-Pugh B/C. General Medicaid contact: 1-866-608-9422. For ADA accommodation completing the form: 801-538-6155.
Yes. Utah voters approved Proposition 3 (full Medicaid expansion to 138% of the federal poverty level) by ballot initiative in November 2018. After several rounds of legislative modification (Utah Senate Bills 96 and 4001 in 2019 attempted partial expansion variants), Utah implemented full Medicaid expansion effective January 1, 2020 covering adults 19-64 at or below 138% FPL. As of 2026, approximately 350,000-400,000 Utahns are enrolled in Medicaid including the expansion population. Utah's expansion status places it among the 41 expansion states. The GLP-1 pilot program coverage applied to all Utah Medicaid enrollees regardless of eligibility pathway during the pilot period, which ended June 30, 2026.
Utah is structurally unique in three ways within the 37-state taxonomy: (1) UTAH WAS THE ONLY STATE IN THE SERIES WITH A LEGISLATIVE PILOT-PROGRAM SUNSET DATE explicitly attached to chronic-weight-management coverage — and the sunset executed: the pilot expired June 30, 2026 without renewal. (2) UTAH USED A UNIFIED 11-PART PA FORM covering all six GLP-1 indications (adult weight loss, pediatric weight loss, Wegovy MACE, Zepbound OSA, Wegovy MASH, reauthorization across all categories) in a single document — most other states use separate PA criteria documents per indication (Arkansas uses three separate documents; West Virginia combines Wegovy CV+MASH but uses separate Zepbound OSA document); the form was reissued June 1, 2026 as 'GLP-1 Medications for Weight-related Comorbidities' covering the three surviving indications. (3) UTAH USES THE STRICTEST OSA CRITERIA in the series — in-lab attended PSG required (not home sleep test), 70% PAP adherence in last 6 months REQUIRED before approval (not just CPAP counseling as in WV), and 70% PAP adherence continuation required for reauth. Utah was among a small group of states with pediatric chronic-weight-management coverage (alongside Mississippi) but only for Wegovy and Saxenda; the reissued form carries no pediatric pathway and Utah's current pediatric coverage status is unverified.
Utah Medicaid appeals run through the Utah Department of Health and Human Services administrative-hearing process. Practical denial-recovery path: (1) contact the Pharmacy PA Team at 855-828-4992 to verify denial rationale; (2) re-submit with additional documentation — for weight management, ensure current weight/height/BMI/dates documented, exercise/diet attestation completed, all six universal criteria attested; for Wegovy MACE, attach formal cardiology consult, ABI report if PAD, evidence of guideline-recommended secondary prevention; for Zepbound OSA, attach the in-lab PSG report with AHI value, the 70% PAP adherence documentation (download report from CPAP device); for Wegovy MASH, attach FIB-4 score calculation + one of liver biopsy/VCTE/ELF/MRE; (3) if denial stands, request administrative hearing through Utah Medicaid; (4) hearing before an administrative law judge; (5) final agency decision; (6) judicial review in Utah district court. The pilot was not extended, so since July 1, 2026 chronic weight management is a non-covered indication for Utah Medicaid GLP-1 approvals — appeals of weight-management denials will be sustained against the patient; the MACE, OSA, and MASH pathways remain appealable on documentation grounds.

Related coverage

  • Mississippi Medicaid GLP-1 Coverage 2026 — the other state with operationalized pediatric (ages 12–17) chronic-weight-management coverage. MS coverage is permanent (SPA 23-0013, effective July 1, 2023); UT coverage was a pilot that expired June 30, 2026 (not renewed).
  • West Virginia Medicaid GLP-1 Coverage 2026 — same three FDA-label carve-outs as UT (Wegovy CV + Wegovy MASH + Zepbound OSA). UT added pilot-program chronic-weight-management coverage through June 30, 2026; WV never did. UT's OSA criteria are stricter (in-lab PSG + 70% PAP adherence required); WV only requires CPAP counseling. UT requires dual-modality MASH confirmation (FIB-4 + imaging/biopsy); WV accepts singly.
  • Oklahoma SoonerCare GLP-1 Coverage 2026 — four FDA-label carve-outs (adds Imcivree monogenic-obesity). Both states are Medicaid expansion states (OK via SQ 802 July 2021; UT effective January 1, 2020). OK uses OU College of Pharmacy / PMC for PA processing; UT uses the standard Utah Medicaid Pharmacy PA Team.
  • Arkansas Medicaid GLP-1 Coverage 2026 — opposite legislative posture: Arkansas's ACT 628 § 20-77-154(c) (effective January 1, 2026) explicitly ratifies the categorical exclusion of weight-loss drugs; Utah's pilot program affirmed temporary coverage, which expired June 30, 2026. Both states use unified or near-unified PA infrastructure (UT: single unified form; AR: three separate DUR-Board documents).
  • GLP-1 Insurance Coverage: Medicare, Medicaid, and Commercial — our state Medicaid coverage series master index.
  • GLP-1 Insurance Dropped Coverage Appeal Playbook — cross-state appeal pathways. Utah: Utah DHHS Medicaid administrative hearing; PA Team Pharmacy line 855-828-4992 for denial-rationale clarification.

Last verified

All primary sources in this article were verified by direct document fetch and full-text extraction on May 15, 2026, and the pilot's expiration was re-verified on August 25, 2026 against the reissued Utah Medicaid PA form “GLP-1 Medications for Weight-related Comorbidities” (Last Updated June 1, 2026, retrieved from medicaid-documents.dhhs.utah.gov/pharmacy/priorauthorization/pdf/GLP-1+Medications+for+Weight-related+Comorbidities.pdf; the pilot-era form URL is no longer served) and Utah News Dispatch reporting (July 6, 2026). Pilot-era sources include: Utah Medicaid Pharmacy Prior Authorization Request Form “GLP-1 Medications for Weight Loss and Other Indications (Saxenda, Wegovy, Zepbound)” (4 pages, last updated January 1, 2026); Utah Medicaid Pharmacy Program page; Utah Medicaid Preferred Drug List page (PDL effective May 1, 2026); Utah Medicaid Prior Authorization page; 42 U.S.C. § 1396r-8(d)(2)(A) (Cornell LII); 42 C.F.R. § 431 Subpart E (federal fair hearings framework). The pilot-program sunset date of June 30, 2026 appeared in three explicit attestations in the pilot-era PA form; the pilot expired on that date without renewal. Confirm current PA criteria at medicaid.utah.gov/pharmacy-program/prior-authorization before making clinical or financial decisions.

This article is for informational purposes only and does not constitute legal, medical, or pharmacy advice. Utah Medicaid policy can change at any time; always confirm current coverage with the Utah Medicaid Pharmacy PA Team (855-828-4992) or General Medicaid (1-866-608-9422) before making clinical or financial decisions.